EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives

Karl-Josef Langen iD, Norbert Galldiks, Jörg Mauler iD, Martin Kocher iD, Christian Peter Filß, Gabriele Stoffels, Cláudia Régio Brambilla iD, Carina Stegmayr, Antje Willuweit iD, Wieland Alexander Worthoff, Nadim Jon Shah iD, Christoph Lerche iD und 2 weitere

Cancers · 12.07.2023 · 15 (14) · 3577

DOI: 10.3390/cancers15143577 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.07.2023. Verfasst von Karl-Josef Langen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience and Medicine (INM-3, INM-4, INM-11), Forschungszentrum Juelich, 52425 Juelich, Germany. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced MRI methods and PET using radiolabelled amino acids provide valuable information, in addition to conventional MR imaging, for brain tumour diagnostics. These methods are particularly helpful in challenging situations such as the differentiation of malignant processes from benign lesions, the identification of non-enhancing glioma subregions, the differentiation of tumour progression from treatment-related changes, and the early assessment of responses to anticancer therapy. The debate over which of the methods is preferable in which situation is ongoing, and has been addressed in numerous studies. Currently, most radiology and nuclear medicine departments perform these examinations independently of each other, leading to multiple examinations for the patient. The advent of hybrid PET/MRI allowed a convergence of the methods, but to date simultaneous imaging has reached little relevance in clinical neuro-oncology. This is partly due to the limited availability of hybrid PET/MRI scanners, but is also due to the fact that PET is a second-line examination in brain tumours. PET is only required in equivocal situations, and the spatial co-registration of PET examinations of the brain to previous MRI is possible without disadvantage. A key factor for the benefit of PET/MRI in neuro-oncology is a multimodal approach that provides decisive improvements in the diagnostics of brain tumours compared with a single modality. This review focuses on studies investigating the diagnostic value of combined amino acid PET and ‘advanced’ MRI in patients with cerebral gliomas. Available studies suggest that the combination of amino acid PET and advanced MRI improves grading and the histomolecular characterisation of newly diagnosed tumours. Few data are available concerning the delineation of tumour extent. A clear additive diagnostic value of amino acid PET and advanced MRI can be achieved regarding the differentiation of tumour recurrence from treatment-related changes. Here, the PET-guided evaluation of advanced MR methods seems to be helpful. In summary, there is growing evidence that a multimodal approach can achieve decisive improvements in the diagnostics of cerebral gliomas, for which hybrid PET/MRI offers optimal conditions.

Schlagwörter

Stichwörter der Autor:innen

Hybrid PET/MRIO-(2-[18F]fluoroethyl)-L-tyrosine (FET)PETbrain tumour diagnosiscerebral gliomamultimodal imagingradiolabelled amino acids

Autor:innen und Institutionen

  • Institute of Neuroscience and Medicine (INM-3, INM-4, INM-11), Forschungszentrum Juelich, 52425 Juelich, Germany.
  • Department of Nuclear Medicine, RWTH Aachen University Hospital, 52074 Aachen, Germany.
  • Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Duesseldorf, 53127 Bonn, Germany.
  • Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
  • Department of Stereotaxy and Functional Neurosurgery, Center for Neurosurgery, Faculty of Medicine, University Hospital Cologne, 50931 Cologne, Germany.
  • Department of Neurology, RWTH Aachen University Hospital, 52074 Aachen, Germany.

ORCID-Profile: Karl-Josef Langen, Jörg Mauler, Martin Kocher, Cláudia Régio Brambilla, Antje Willuweit, Nadim Jon Shah, Christoph Lerche, Felix Manuel Mottaghy, Philipp Lohmann

Zitieren

APA

Langen, K. J., Galldiks, N., Mauler, J., Kocher, M., Filß, C. P., Stoffels, G., Régio Brambilla, C., Stegmayr, C., Willuweit, A., Worthoff, W. A., Shah, N. J., Lerche, C., Mottaghy, F. M., & Lohmann, P. (2023). Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives. Cancers, 15(14), 3577. https://doi.org/10.3390/cancers15143577

Vancouver

Langen KJ, Galldiks N, Mauler J, Kocher M, Filß CP, Stoffels G, et al. Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives. Cancers. 2023;15(14):3577. doi:10.3390/cancers15143577

BibTeX
@article{Langen2023,
  author = {Langen, Karl-Josef and Galldiks, Norbert and Mauler, Jörg and Kocher, Martin and Filß, Christian Peter and Stoffels, Gabriele and Régio Brambilla, Cláudia and Stegmayr, Carina and Willuweit, Antje and Worthoff, Wieland Alexander and Shah, Nadim Jon and Lerche, Christoph and Mottaghy, Felix Manuel and Lohmann, Philipp},
  title = {Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {14},
  pages = {3577},
  doi = {10.3390/cancers15143577}
}
Kostenlos starten →